Literature DB >> 33607835

Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report.

Zhengwei Zhang1, Xiaona Bao, Zhifeng Wu, Jie Zhang.   

Abstract

RATIONALE: Half-dose or reduced-fluence photodynamic therapy (PDT) with verteporfin has been well acknowledged to be the most effective and permanent treatment with very low rates of complications. However, we report a case of chronic central serous chorioretinopathy (CSC) who developed choroidal neovascularization (CNV) secondary to half-dose PDT within only 3 weeks. Such an occurrence following this short a course of treatment has not been reported previously. PATIENT CONCERNS: A 46-year-old Chinese man who had been diagnosed as acute more than 1 year ago revisited our department recently and complained of blurred vision again in his left eye. DIAGNOSES: Fluorescein fundus angiography (FFA) and indocyanine green angiography (ICGA) revealed patchy hyperfluorescent dots and optical coherence tomography (OCT) indicated irregular flat pigment epithelium detachment (PED) in the central macula. The patient was diagnosed with chronic CSC.
INTERVENTIONS: The patient was treated by half-dose PDT with verteporfin. Three weeks later, the patient complained of sudden blurred vision and fundus examination showed macular hemorrhages with a best-corrected visual acuity (BCVA) of 20/250. OCT angiography (OCTA) showed a distinct area of flower-like CNV located within the deep retinal slab. Secondary CNV had developed after a quite short course of half-dose PDT treatment. Subsequently, the patient was administered by 2 intravitreal injections of aflibercept (2 mg). OUTCOMES: Two months after the second intravitreal injection, macular hemorrhages and secondary CNV were completely resolved, and the BCVA improved to 20/25. LESSONS: Patients of chronic CSC with irregular PED who undergo PDT should be warned of secondary CNV within a short course after treatment. If happened, it should be treated by intravitreal injections of anti-vascular endothelial growth factor agents as soon as possible.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33607835      PMCID: PMC7899877          DOI: 10.1097/MD.0000000000024790

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  14 in total

1.  Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy.

Authors:  Michael Colucciello
Journal:  Retina       Date:  2006-02       Impact factor: 4.256

2.  Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.

Authors:  Ali Demircan; Ceren Yesilkaya; Zeynep Alkin
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-02-02       Impact factor: 3.631

3.  PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.

Authors:  Sungsoon Hwang; Se Woong Kang; Sang Jin Kim; Jun Won Jang; Kyung Tae Kim
Journal:  Retina       Date:  2019-06       Impact factor: 4.256

4.  PHOTODYNAMIC THERAPY-INDUCED ACUTE EXUDATIVE MACULOPATHY: Incidence, Clinical Features, and Long-Term Outcomes.

Authors:  George Joseph Manayath; Ratnesh Ranjan; Swapnil Vidhate; Venkatapathy Narendran
Journal:  Retina       Date:  2020-01       Impact factor: 4.256

Review 5.  Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities.

Authors:  Rebecca Kaye; Shruti Chandra; Jay Sheth; Camiel J F Boon; Sobha Sivaprasad; Andrew Lotery
Journal:  Prog Retin Eye Res       Date:  2020-05-11       Impact factor: 21.198

6.  A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.

Authors:  Mingwei Zhao; Feng Zhang; Youxin Chen; Hong Dai; Jinfeng Qu; Chongya Dong; Xiaoping Kang; Yuling Liu; Liu Yang; Yibin Li; Peng Zhou; Chung-Ting Pan; Lijuan Zhang; Peipei Liu; Haiying Zhou; Xuan Jiao; Ying Xiong; Rong Tian; Yingyi Lu; Xiaobing Yu; Xiaoxin Li
Journal:  JAMA Ophthalmol       Date:  2015-03       Impact factor: 7.389

Review 7.  Central serous chorioretinopathy: Towards an evidence-based treatment guideline.

Authors:  Thomas J van Rijssen; Elon H C van Dijk; Suzanne Yzer; Kyoko Ohno-Matsui; Jan E E Keunen; Reinier O Schlingemann; Sobha Sivaprasad; Giuseppe Querques; Susan M Downes; Sascha Fauser; Carel B Hoyng; Felice Cardillo Piccolino; Jay K Chhablani; Timothy Y Y Lai; Andrew J Lotery; Michael Larsen; Frank G Holz; K Bailey Freund; Lawrence A Yannuzzi; Camiel J F Boon
Journal:  Prog Retin Eye Res       Date:  2019-07-15       Impact factor: 21.198

8.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

9.  Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Lawrence A Yannuzzi; Jason S Slakter; Nicole E Gross; Richard F Spaide; Danielle L L Costa; Sheau J Huang; James M Klancnik; Alexander Aizman
Journal:  Retina       Date:  2003-06       Impact factor: 4.256

Review 10.  Central Serous Chorioretinopathy: Pathogenesis and Management.

Authors:  Francesco Semeraro; Francesco Morescalchi; Andrea Russo; Elena Gambicorti; Andrea Pilotto; Francesco Parmeggiani; Silvia Bartollino; Ciro Costagliola
Journal:  Clin Ophthalmol       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.